Literature DB >> 19959640

Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis.

Sirichai Pasadhika1, Gerald A Fishman, Edwin M Stone, Martin Lindeman, Ruth Zelkha, Irma Lopez, Robert K Koenekoop, Mahnaz Shahidi.   

Abstract

PURPOSE: To evaluate genotypic and macular morphologic correlations in patients with RPE65-, CEP290-, GUCY2D-, or AIPL1-related Leber congenital amaurosis (LCA) using spectral-domain optical coherence tomography (SD-OCT).
METHODS: SD-OCT macular scans were performed in 21 patients, including 10 with RPE65, 7 with CEP290, 3 with GUCY2D, and 1 with AIPL1 mutations. An image processing software was used to manually draw segmentation lines by three observers. Lamellar structure was evaluated based on the number of retinal layers on segmented images. Total retinal thickness was measured at the central macular and perifoveal areas by using an automated algorithm.
RESULTS: All three patients with GUCY2D mutations (age range, 20-53 years) retained six retinal layers with visible photoreceptor inner/outer segment juncture (PSJ). However, the preservation of lamellar structures did not parallel better visual acuity. Patients with other mutations had poorly defined PSJ and disorganized retinal lamellar structures, where only one to three retinal layers could be observed. Patients with CEP290 mutations trended to have retention of the outer nuclear layer at the fovea and macular thickening, especially at younger ages. In patients with RPE65 (age range, 20-71 years) and AIPL1 mutations (age, 22 years), macular thickness was markedly decreased. Disorganization of retinal lamellar structures in the RPE65 group trended toward a worsening with increasing age.
CONCLUSIONS: Variations of macular microstructures were observed among LCA patients with different genotypes. Disorganization of retinal lamellar structure was generally age related. Preservation of retinal microanatomic structures may not be associated with better visual acuity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959640      PMCID: PMC2868490          DOI: 10.1167/iovs.09-3734

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  26 in total

1.  Clinicopathologic effects of mutant GUCY2D in Leber congenital amaurosis.

Authors:  Ann H Milam; Mark R Barakat; Nisha Gupta; Linda Rose; Tomas S Aleman; Michael J Pianta; Artur V Cideciyan; Val C Sheffield; Edwin M Stone; Samuel G Jacobson
Journal:  Ophthalmology       Date:  2003-03       Impact factor: 12.079

2.  X-linked retinitis pigmentosa. Profile of clinical findings.

Authors:  G A Fishman; M D Farber; D J Derlacki
Journal:  Arch Ophthalmol       Date:  1988-03

3.  Mutational analysis and clinical correlation in Leber congenital amaurosis.

Authors:  S R Dharmaraj; E R Silva; A L Pina; Y Y Li; J M Yang; C R Carter; M K Loyer; H K El-Hilali; E K Traboulsi; O K Sundin; D K Zhu; R K Koenekoop; I H Maumenee
Journal:  Ophthalmic Genet       Date:  2000-09       Impact factor: 1.803

4.  The phenotype of Leber congenital amaurosis in patients with AIPL1 mutations.

Authors:  Sharola Dharmaraj; Bart P Leroy; Melanie M Sohocki; Robert K Koenekoop; Isabelle Perrault; Khalid Anwar; Shagufta Khaliq; R Summathi Devi; David G Birch; Elaine De Pool; Natalio Izquierdo; Lionel Van Maldergem; Mohammad Ismail; Annette M Payne; Graham E Holder; Shomi S Bhattacharya; Alan C Bird; Josseline Kaplan; Irene H Maumenee
Journal:  Arch Ophthalmol       Date:  2004-07

5.  Leber's congenital amaurosis.

Authors:  K Mizuno; Y Takei; M L Sears; W S Peterson; R E Carr; L M Jampol
Journal:  Am J Ophthalmol       Date:  1977-01       Impact factor: 5.258

6.  Macular colobomas in Leber's congenital amaurosis.

Authors:  S Margolis; B M Scher; R E Carr
Journal:  Am J Ophthalmol       Date:  1977-01       Impact factor: 5.258

7.  High hyperopia in Leber's congenital amaurosis.

Authors:  R S Wagner; A R Caputo; L B Nelson; D Zanoni
Journal:  Arch Ophthalmol       Date:  1985-10

8.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.

Authors:  William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Artur V Cideciyan; Sharon B Schwartz; Lili Wang; Thomas J Conlon; Sanford L Boye; Terence R Flotte; Barry J Byrne; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695

9.  Yellowish flecks in Leber's congenital amaurosis.

Authors:  E Chew; A Deutman; A Pinckers; A Aan de Kerk
Journal:  Br J Ophthalmol       Date:  1984-10       Impact factor: 4.638

View more
  47 in total

Review 1.  The retinal pigment epithelium in health and disease.

Authors:  J R Sparrow; D Hicks; C P Hamel
Journal:  Curr Mol Med       Date:  2010-12       Impact factor: 2.222

Review 2.  Gene therapy for Leber congenital amaurosis: advances and future directions.

Authors:  Robert B Hufnagel; Zubair M Ahmed; Zélia M Corrêa; Robert A Sisk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-29       Impact factor: 3.117

3.  Mutations in RD3 are associated with an extremely rare and severe form of early onset retinal dystrophy.

Authors:  Markus N Preising; Nora Hausotter-Will; Manuel C Solbach; Christoph Friedburg; Franz Rüschendorf; Birgit Lorenz
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-08       Impact factor: 4.799

4.  Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.

Authors:  Erin R Burnight; Manav Gupta; Luke A Wiley; Kristin R Anfinson; Audrey Tran; Robinson Triboulet; Jeremy M Hoffmann; Darcey L Klaahsen; Jeaneen L Andorf; Chunhua Jiao; Elliott H Sohn; Malavika K Adur; Jason W Ross; Robert F Mullins; George Q Daley; Thorsten M Schlaeger; Edwin M Stone; Budd A Tucker
Journal:  Mol Ther       Date:  2017-06-12       Impact factor: 11.454

5.  Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis.

Authors:  Cristy A Ku; Vince A Chiodo; Sanford L Boye; Andrew F X Goldberg; Tiansen Li; William W Hauswirth; Visvanathan Ramamurthy
Journal:  Hum Mol Genet       Date:  2011-08-31       Impact factor: 6.150

Review 6.  A comprehensive review of retinal gene therapy.

Authors:  Shannon E Boye; Sanford L Boye; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

7.  Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Igor V Peshenko; Alexander Sumaroka; Elena V Olshevskaya; Lihui Cao; Sharon B Schwartz; Alejandro J Roman; Melani B Olivares; Sam Sadigh; King-Wai Yau; Elise Heon; Edwin M Stone; Alexander M Dizhoor
Journal:  Hum Mol Genet       Date:  2012-10-03       Impact factor: 6.150

8.  Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque.

Authors:  K Tyler McCullough; Sanford L Boye; Diego Fajardo; Kaitlyn Calabro; James J Peterson; Christianne E Strang; Dibyendu Chakraborty; Sebastian Gloskowski; Scott Haskett; Steven Samuelsson; Haiyan Jiang; C Douglas Witherspoon; Paul D Gamlin; Morgan L Maeder; Shannon E Boye
Journal:  Hum Gene Ther       Date:  2018-12-20       Impact factor: 5.695

9.  CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype.

Authors:  E R Burnight; L A Wiley; A V Drack; T A Braun; K R Anfinson; E E Kaalberg; J A Halder; L M Affatigato; R F Mullins; E M Stone; B A Tucker
Journal:  Gene Ther       Date:  2014-05-08       Impact factor: 5.250

10.  Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse.

Authors:  Shannon E Boye; Sanford L Boye; Jijing Pang; Renee Ryals; Drew Everhart; Yumiko Umino; Andy W Neeley; Joseph Besharse; Robert Barlow; William W Hauswirth
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.